HFSA 2026: ATTRibute-CM Analysis; LINK-HF2 Results; More
New science presented at HFSA 2026 and simultaneously published in JACC: Heart Failure spans several evolving areas in heart failure (HF), from ATTR-CM biomarkers and measures of physical function to predictors of adverse outcomes in transplant recipients to artificial intelligence (AI) wearables enhancing discharge care following HF hospitalization.
ACC-Supported Radiation Safety Coalition Seeks Clinician Input
The ACC and the ALARA+ Coalition are seeking input from cardiovascular clinicians and health care facility administrators to help better understand the real-world impacts of occupational radiation exposure and inform future workplace safety efforts.
ACCEL Lite: TRANQUILITY: IL-6, An Important Mediator of CVD
In this episode, Dipti Itchhaporia MD, MACC and Deepak L. Bhatt, MD, MPH, MBA, FACC discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk.
CKM Syndrome: Insights From and Comparison of Recent Guidelines
The 2026 ACC/AHA/Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome provides an expanded framework for assessing and managing interconnected metabolic risk factors…
FDA Update: Agency Warns of Transcatheter MV Delivery System Issue
The U.S. Food and Drug Administration (FDA) has issued an Early Alert, warning that Edwards Lifesciences is recommending certain delivery systems used for the SAPIEN M3 transcatheter mitral valve (MV) replacement be removed from use.
Pullback Pressure Gradient: Unlocking the Functional Map of CAD
Coronary angiography has long served as the anatomical cornerstone for guiding PCI. Yet, the visual severity of a stenosis does not always reflect its physiological significance.
Interventional Post-ACS Antithrombotic Trials at ESC Congress 2026
Four late-breaking trials, presented at ESC Congress 2026 focused on post-acute coronary syndrome (ACS) antithrombotic therapy.
Sports Cardiology Research and Guideline Highlights: Early 2026
The 2026 ESC/ACC clinical consensus statement on Masters Athletes With Abnormal Cardiovascular Findings is guided by a clinical consensus statement outlining expert recommendations for the diagnostic assessment, management, and risk stratification of cardiac abnormalities in masters athletes (MAs).
Structural Heart Disease Trials Featured at ESC Congress 2026
Four late-breaking trials presented at ESC Congress 2026 offer new insights into the management of structural heart disease and heart failure (HF).
ACC Scientific Statement Calls For Exercise Prescription as Key Element of Routine CV Care
Exercise should be prescribed as a foundational component of routine cardiovascular care, according to a new ACC Scientific Statement on Exercise Prescriptions for Cardiovascular Health in Adults. Read the full statement in JACC.
